InflaRx (IFRX) investor relations material

Strategic focus and pipeline overview

• Focused on developing proprietary anti-C5a and C5aR inhibitors for inflammatory diseases, with lead oral candidate izicopan showing biologic-like efficacy in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU).

• Corporate strategy streamlined to prioritize izicopan in the broader immunology and inflammation (I&I) space, with strong IP protection and cash runway into mid-2027.

• Additional assets include vilobelimab, an IV monoclonal antibody targeting C5a, approved for ARDS in Europe and under further development in large-scale trials.

Differentiation and market opportunities

• Izicopan demonstrates superior pharmacokinetics and tissue penetration compared to avacopan, with faster achievement of therapeutic plasma levels and higher inhibitory potential.

• Safety profile is favorable, with minimal CYP3A4/5 inhibition and no significant safety signals in over 100 subjects dosed.

• Market opportunities identified in HS, CSU, and ANCA-associated vasculitis, with the latter representing a $1B+ commercial potential.

• Differentiation from competitors includes potential for corticosteroid-sparing labeling and simplified dosing.

Clinical data highlights

• Phase II HS study showed rapid and deep reductions in abscesses, nodules, and draining tunnels, especially in the high-dose group, with 50% of patients achieving zero draining tunnels at week four.

• Continued improvement observed after drug discontinuation, with HiSCR response rates increasing up to 63% in the high-dose group by week eight.

• Significant and early pain reduction reported, with up to 75% of patients achieving a 30% improvement in skin pain within four weeks.

• CSU data showed meaningful reductions in Urticaria Activity Score 7, particularly in more severe patients, supporting further exploration.